Monitoring Urinary CK19 Fragment in Urinary Tumor by Using Electrochemiluminescence Immunoassay

张忠英,叶辉铭,廖爱能,林永志,傅必成

DOI: https://doi.org/10.3969/j.issn.1672-4194.2004.01.020

2004-01-01

Abstract:Objective Monitoring urinary cytokeratin 19 fragment(CK19, Cyfra21|1) for diagnosis of urinary bladder cancer. Methods Urinary CK19 was investigated by using an electrochemiluminescent immunoassay(ECLIA) in urine samples of 84 healthy subjects and 139 patients including 71 with bladder cancer, 9 with other urological cancers and 59 with acute urological infection diseases. 26 patients were investigated again within a month. Results The mean urinary CK19 in patients suffered from bladder cancer was 177 2±66 7 μg/L that was significantly different from those in healthy control(1 6±0 9 μg/L,P0 01), acute urinary tract infection(6 9±1 12 μg/L,P0 01) and other urological cancers(45 0±32 6 μg/L, P0 05). The cutoff that was obtained by the 99% percentile in healthy subjects was ≤ 3 9 μg/L. With this cutoff the overall sensitivity was 92 5%, specificities was 82 7%. The false|positive rate was 50 8% in acute urological infection diseases. After antiphlogistic the urine CK19 level of 17 patients(17/18) with acute urological infection disease were decreased within a month and contractedly the urine CK19 level of 8 patients with bladder cancer maintained higher. Conclusion Urinary CK19 level is an useful parameter for selecting high risk patients with bladder cancer for a more oriented cystoscopy and monitoring urinary cytokeratin 19 fragment(CK19, Cyfra21|1) of patients can decline the false positive rate, raising overall specificities and positive predictive value.